Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track

Tenaya Therapeutics, Inc.

2023-Q1 EPS reported -$0.75

Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.
Net loss of $31.1M ($0.75/sh) for Q1 2022; R&D expense $24.2M, G&A $7.0M.
TN-201 received EU Orphan Medicinal Product designation for MYBPC3 HCM; IND expected H2 2022.
Preclinical TN-401 data at Heart Rhythm 2022 showed restored heart function, reduced arrhythmia, increased survival; IND expected 2023.
cGMP manufacturing facility in Union City expected operational H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.